scholarly journals Prospects of plasmapheresis for patients with severe COVID-19

2020 ◽  
Author(s):  
Ilmira R. Gilmutdinova ◽  
Maksim Yu. Yakovlev ◽  
Petr S. Eremin ◽  
Anatoliy D. Fesun
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Distress Syndrome ◽  
International Committee ◽  
World Health ◽  
Cytokine Storm ◽  
Positive Experience ◽  
Cytokine Levels ◽  
The World ◽  
Health Organization

On February 11, 2020, the World Health Organization officially named the infection caused by the new coronavirus “Coronavirus disease 2019” (COVID-19). On February 11, 2020, the International Committee on Taxonomy of Viruses (ICTV) officially named the infectious matter “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). Emergence of severe complications with new coronavirus disease is due to the development of hypercytokinaemia, also known as “cytokine storm”. These complications comprise acute respiratory distress syndrome (ARDS), respiratory failure and death. Emerging data point to the logic of using extracorporeal haemocorrection to normalise cytokine levels and reduce the severity of organ disorders. The analysis of the literature indicates that to date, a certain positive experience has been accumulated in the world in the application of extracorporeal methods in clinical practice in patients with COVID-19.

scholarly journals Prospects of plasmapheresis for patients with severe COVID-19

2020 ◽  
Vol 30 (3) ◽  
Author(s):  
Ilmira R. Gilmutdinova ◽  
Maksim Yu. Yakovlev ◽  
Petr S. Eremin ◽  
Anatoliy D. Fesun
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Distress Syndrome ◽  
International Committee ◽  
World Health ◽  
Cytokine Storm ◽  
Positive Experience ◽  
Cytokine Levels ◽  
The World ◽  
Health Organization

On February 11, 2020, the World Health Organization officially named the infection caused by the new coronavirus “Coronavirus disease 2019” (COVID-19). On February 11, 2020, the International Committee on Taxonomy of Viruses (ICTV) officially named the infectious matter “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). Emergence of severe complications with new coronavirus disease is due to the development of hypercytokinaemia, also known as “cytokine storm”. These complications comprise acute respiratory distress syndrome (ARDS), respiratory failure and death. Emerging data point to the logic of using extracorporeal haemocorrection to normalise cytokine levels and reduce the severity of organ disorders. The analysis of the literature indicates that to date, a certain positive experience has been accumulated in the world in the application of extracorporeal methods in clinical practice in patients with COVID-19.

scholarly journals Markers Associated with COVID-19 Susceptibility, Resistance, and Severity

Viruses ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 45
Author(s):  
Aisha D. Fakhroo ◽  
Asmaa A. Al Thani ◽  
Hadi M. Yassine
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Mortality Rate ◽  
Distress Syndrome ◽  
Immune Reaction ◽  
Severe Infection ◽  
World Health ◽  
Cytokine Storm ◽  
Factors Associated ◽  
The World ◽  
Health Organization

In December 2019, the latest member of the coronavirus family, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, leading to the outbreak of an unusual viral pneumonia known as coronavirus disease 2019 (COVID-19). COVID-19 was then declared as a pandemic in March 2020 by the World Health Organization (WHO). The initial mortality rate of COVID-19 declared by WHO was 2%; however, this rate has increased to 3.4% as of 3 March 2020. People of all ages can be infected with SARS-CoV-2, but those aged 60 or above and those with underlying medical conditions are more prone to develop severe symptoms that may lead to death. Patients with severe infection usually experience a hyper pro-inflammatory immune reaction (i.e., cytokine storm) causing acute respiratory distress syndrome (ARDS), which has been shown to be the leading cause of death in COVID-19 patients. However, the factors associated with COVID-19 susceptibility, resistance and severity remain poorly understood. In this review, we thoroughly explore the correlation between various host, viral and environmental markers, and SARS-CoV-2 in terms of susceptibility and severity.

OBESITY IN SARS-COV-2 INFECTION: LITERATURE REVIEW

2021 ◽  
pp. 19-23
Author(s):  
Donizete Tavares Da Silva ◽  
Priscila De Sousa Barros Lima ◽  
Renato Sampaio Mello Neto ◽  
Gustavo Magalhães Valente ◽  
Débora Dias Cabral ◽  
...  
Keyword(s):  
Public Health ◽  
Acute Respiratory Distress Syndrome ◽  
Gastrointestinal Tract ◽  
Severe Acute Respiratory Syndrome ◽  
Distress Syndrome ◽  
Circulatory System ◽  
World Health ◽  
Global Public Health ◽  
The World ◽  
Health Organization

In March 2020, the World Health Organization (1) declared COVID-19 as a pandemic and a threat to global public health (2). The virus mainly affects the lungs and can cause acute respiratory distress syndrome (ARDS). In addition, coronavirus 2 severe acute respiratory syndrome (SARSCOV2) also has devastating effects on other important organs, including the circulatory system, brain, gastrointestinal tract, kidneys and liver

scholarly journals How to Control Covid-19 with a Nanobiotherapy?

2020 ◽  
Keyword(s):  
Intensive Care Unit ◽  
Immune Response ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Multiple Organ ◽  
World Health ◽  
Shortness Of Breath ◽  
The World ◽  
Health Organization ◽  
Muscle Ache

The outbreak of emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) in China has been brought to global attention and declared a pandemic by the World Health Organization (WHO) on March 11, 2020. In a recent study of Nanshan Chen et al., on patients of Wuhan Jinyintan Hospital, Wuhan, China, from the 99 patients with SARSCoV-2 infection, 51% had chronic diseases and they had symptoms of fever (83%), cough (82%) shortness of breath (31%), muscle ache (11%), fatigue (9%), headache (8%), sore throat (5%), rhinorrhea (4%), chest pain (2%), diarrhea (2%), and nausea and vomiting (1%) [1, 2]. The majority of patients can recover, however, about 25% of patients will progress into severe complications including acute respiratory distress syndrome (ARDS), which may worsen rapidly into respiratory failure, need an intensive care unit (ICU) and even cause multiple organ failure [3]. Depending on the pathophysiological mechanisms supposed to be involved in the development of the various clinical forms of the disease, various types of treatment have been tested with varying degrees of success. We have developed a nanotherapy to block the entry of the virus into the host cell, to reduce its potential for replication and to regulate the immune response against the microbial aggressor [4].

scholarly journals COVID-19- or Tramadol-induced Seizure: A Differential Diagnosis in Young People

2020 ◽  
Vol 10 (4) ◽  
pp. 32009.1-32009.2
Author(s):  
Solmaz Nekoueifard ◽  
◽  
Mohammad Majidi ◽  
Keyword(s):  
Myocardial Infarction ◽  
Acute Kidney Injury ◽  
Differential Diagnosis ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Kidney Injury ◽  
World Health ◽  
The World ◽  
Life Threatening ◽  
Health Organization

Coronavirus disease 2019 (COVID-19) was first declared in December 2019 from Wuhan, China [1, 2]. It then has been reported a pandemic in March 2020 by the World Health Organization [3]. Clinical features of COVID-19 are different from asymptomatic to mild to moderate symptoms, such as fever, headache, myalgia, sore throat, anosmia, cough, fatigue headache, hemoptysis, and dyspnea to the life-threatening complications, including shock, pneumonia, acute respiratory distress syndrome, myocarditis, myocardial infarction, acute kidney injury, multi-organ failure, and even death [1, 2].

scholarly journals Pathomorphological Changes In The Lungs Of COVID-19 Patients

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Zeshan Ali
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Multiple Organ ◽  
World Health ◽  
Severe Respiratory Failure ◽  
Novel Virus ◽  
Health Organization

In December 2019, a novel virus was discovered in China causing severe acute respiratory distress syndrome and the virus was designated as SARS-CoV-2 [1]. On 11th March 2020, the Corona Virus (SARS-CoV-2) was declared a pandemic by World Health Organization (WHO) [2]. Millions of people worldwide have been affected by this virus [3]. Most of the patients shows mild symptoms. Severe cases lead to the death of patients due to severe respiratory failure. Multiple organ failure has been seen in many patients suffering from COVID-19

scholarly journals Multiorgan Involvement in COVID-19 and Possible Therapies

2020 ◽  
Vol 04 (01) ◽  
pp. 20-24
Author(s):  
Prachee Sathe ◽  
Vijay Sundar Singh
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
World Health Organization ◽  
Distress Syndrome ◽  
Respiratory Illness ◽  
World Health ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

AbstractIn late 2019, China reported cases of respiratory illness in humans, which involved a novel Coronavirus SARS-CoV-2 (also known as 2019-nCoV). The World Health Organization (WHO) termed the disease COVID-19 (i.e., Coronavirus disease 2019). Most of the morbidity and mortality from COVID-19 is largely due to acute viral pneumonitis that leads to acute respiratory distress syndrome (ARDS). This article will discuss the clinical features of the multiorgan involvement in COVID-19 as well as the management of patients who become critically ill due to COVID-19.

The Platelet Role in Severe and Fatal Forms of COVID-19.

2021 ◽  
Vol 21 ◽  
Author(s):  
Edgar L. Esparza-Ibarra ◽  
Jorge L. Ayala-Luján ◽  
Brenda Mendoza-Almanza ◽  
Irma González-Curiel ◽  
Susana Godina-González ◽  
...  
Keyword(s):  
World Health Organization ◽  
Causes Of Death ◽  
Distress Syndrome ◽  
Severe Disease ◽  
World Health ◽  
Cytokine Storm ◽  
The World ◽  
Critical Patients ◽  
Health Organization ◽  
Coagulation Dysfunction

: On December 31, 2019, the World Health Organization received a report of several pneumonia cases in Wuhan, China. The causative agent was later confirmed as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Since then, the SARS-CoV-2 virus has spread throughout the world, giving rise in 2020 to the 2019 coronavirus (COVID-19) pandemic, which, according to the world map of the World Health Organization, has, until May 18, 2021, infected 163,312,429 people and caused 3,386,825 deaths throughout the world. Most critical patients progress rapidly to acute respiratory distress syndrome (ARDS) and, in underlying form, to septic shock, irreversible metabolic acidosis, blood coagulation dysfunction, or hemostatic and thrombotic anomalies have been reported as the leading causes of death due to COVID-19. The main findings in severe and fatal COVID-19 patients make it clear that platelets play a crucial role in developing severe disease cases. Platelets are the enucleated cells responsible for hemostasis and thrombi formation; thus, platelet hyperreactivity induced by pro-inflammatory microenvironments contributes to the "cytokine storm" that characterizes the more aggressive course of COVID- 19.

Cytokine storm syndrome in SARS-CoV-2: a review

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Braira Wahid ◽  
Noshaba Rani ◽  
Muhammad Idrees
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Cytokine Storm ◽  
Global Level ◽  
Management Option ◽  
Human Contact

Abstract After wreaking havoc on a global level with a total of 5,488,825 confirmed cases and 349,095 deaths as of May 2020, severe acute respiratory syndrome coronavirus 2 is truly living up to the expectations of a 21st-century pandemic. Since the major cause of mortality is a respiratory failure from acute respiratory distress syndrome, the only present-day management option is supportive as the transmission relies solely on human-to-human contact. Patients suffering from coronavirus disease 2019 (COVID-19) should be tested for hyper inflammation to screen those for whom immunosuppression can increases chances of survival. As more and more clinical data surfaces, it suggests patients with mild or severe cytokine storms are at greater risk of failing fatally and hence these cytokine storms should be targets for treatment in salvaging COVID-19 patients.

CORONOVIRUS INFECTION COVID-19. MASKS (literature review)

2021 ◽  
Vol 7 (1) ◽  
pp. 24-32
Author(s):  
Semen Kireev ◽  
I. Popov ◽  
A. Ban'kovskiy ◽  
E. Litvinenko ◽  
E. Surova
Keyword(s):  
World Health Organization ◽  
Infectious Agent ◽  
International Committee ◽  
World Health ◽  
Vulnerable Communities ◽  
Regional Director ◽  
The World ◽  
Coronavirus Infection ◽  
Health Organization ◽  
The City

At the end of 2019, an outbreak of a new coronavirus infection occurred in the People's Re-public of China with an epicenter in the city of Wuhan (Hubei province). On February 11, 2020, the World Health Organization has assigned the official name of the infection caused by the new coronavirus - COVID-19 ("Coronavirus disease2019"). On February 11, 2020, the International Committee on Virus Taxonomy gave the official name to the infectious agent - SARS-CoV-2.Since the end of January 2020, cases of COVID-19 have begun to be registered in many coun-tries of the world, mainly associated with travel to the PRC. At the end of February 2020, the epidemiological situation with COVID-19 in South Korea, Iran and Italy sharply worsened, which subsequently led to a significant increase in the number of cases in other countries of the world associated with travel to these countries, incl. and in Russia. The World Health Organiza-tion announced the COVID-19 pandemic on 11 March 2020, and the pandemic's challenge to the world will remain so as long as people are not immune to it.The Regional Director of the World Health Organization Takeshi Kasai, on the basis of an epidemiological analysis, reports that the spread of coronavirus infection COVID-19 in July-August 2020 occurred mainly among people under 50 years old, and they often did not even know about it, because they had mild or no symptoms. In the future, these people then infect older people who are more difficult to tolerate COVID-19. And we need to redouble our efforts to prevent the spread of the virus in vulnerable communities.

Sign in / Sign up

Export Citation Format

Share Document